Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON
2022-002538-14Phase 2Active
- Sponsor
- GSK
- Start
- Oct 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing GSK4532990 with Placebo (2 arms). Primary endpoint: Fibrosis improvement without worsening of NASH at 52 weeks. Started Oct 2022; status: active.
02
Drugs
GSK4532990
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2022-002538-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002538-14.